The US Food and Drug Administration has released information on the BoiNtech/Pfizer coronavirus vaccine ahead of its meeting to consider emergency certification in the USA. It is noteworthy that the definition of a "case" is quite different from that used for the Oxford/AstraZeneca vaccine so that the claimed efficacies are not comparable. For the BioNtech/Pfizer vaccine a swab is taken when an acute respiratory illness develops. For the Oxford/AstraZeneca vaccine weekly swabs are taken.
A peer-reviewed account of the interim results of the Oxford AstraZeneca Covid-19 vaccine (ChAdOx1) trials has appeared as an article in The Lancet . 23,848 people took part. Analysis of efficacy was based on weekly self-administered postal PCR swab tests in the UK arm of the trial. Altogether 30 participants who had received the vaccine and 101 who received the control had detectable Covid-19.